At the news
? NEUTRALIMPACT 4/10 SC 13G/A filed Nov 20, 2026 at 13:27 ET
Propel Bio Management LLC and affiliated entities filed an amended Schedule 13G disclosing beneficial ownership of 12,615,010 shares (10.1%) of Milestone Pharmaceuticals as of November 19, 2026. This is a new passive stake filing by Propel Bio, a healthcare-focused investment firm, representing a 10.1% position in the micro-cap biotech.
- Propel Bio Management LLC and affiliated entities (Leen Kawas, Richard Kayne, Propel Bio Partners LLC) filed a Schedule 13G/A disclosing 12,615,010 shares of Milestone Pharmaceuticals.
- The stake represents 10.1% of the 124,498,693 common shares outstanding as of November 13, 2026.
- 9,615,010 shares are held by private investment funds and an investment company for which Propel Bio Management and Leen Kawas provide advisory services.
- 3,000,000 shares are held by the Richard and Suzanne Kayne Living Trust, of which Richard Kayne is sole trustee.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access